Related Experiment Video
Updated: Feb 24, 2026

Isolation, Culture, and Functional Characterization of Adult Mouse Cardiomyoctyes
Published on: September 24, 2013
Nebivolol Desensitizes Myofilaments of a Hypertrophic Cardiomyopathy Mouse Model
Sabrina Stücker1,2, Nico Kresin1,2, Lucie Carrier1,2
1Department of Experimental Pharmacology and Toxicology, Cardiovascular Research Center, University Medical Center Hamburg-EppendorfHamburg, Germany.
Insights
Nebivolol desensitized cardiac muscle to calcium in a mouse model of hypertrophic cardiomyopathy (HCM). However, nebivolol did not affect calcium sensitivity in human HCM cardiac muscle.
Area of Science:
- Cardiovascular Research
- Molecular Cardiology
- Pharmacology
Background:
- Hypertrophic cardiomyopathy (HCM) is characterized by diastolic dysfunction and preserved systolic function.
- Current therapies target hypercontractility via beta-blockers and calcium channel blockers.
- Increased myofilament calcium sensitivity is a key mechanism in HCM's hypercontractile phenotype.
Purpose of the Study:
- To evaluate nebivolol's effect on cardiac muscle strips from a Mybpc3-targeted knock-in (KI) HCM mouse model.
- To investigate nebivolol and epigallocatechin-gallate's actions on human HCM cardiac strips with MYBPC3 mutations.
Main Methods:
- Skinned ventricular muscle strips from Mybpc3 KI and wild-type (WT) mice were used.
- Contractile parameters and force-calcium relationships were assessed.
- Human cardiac strips from three MYBPC3-mutated HCM patients were analyzed.
Main Results:
- Nebivolol induced myofilament calcium desensitization in both WT and KI mouse cardiac strips.
- This calcium desensitization was more pronounced in KI mouse strips.
- Nebivolol showed no effect on calcium sensitivity in human HCM cardiac muscle strips.
Conclusions:
- Nebivolol demonstrates potential for myofilament calcium desensitization in an HCM mouse model.
- The drug's efficacy differs between mouse models and human HCM cardiac tissue.
- Further research is needed to understand nebivolol's therapeutic potential in human HCM.
Abstract:
Background: Hypertrophic cardiomyopathy (HCM) patients often present with diastolic dysfunction and a normal to supranormal systolic function. To counteract this hypercontractility, guideline therapies advocate treatment with beta-adrenoceptor and Ca2+ channel blockers. One well established pathomechanism for the hypercontractile phenotype frequently observed in HCM patients and several HCM mouse models is an increased myofilament Ca2+ sensitivity. Nebivolol, a commonly used beta-adrenoceptor antagonist, has been reported to lower maximal force development and myofilament Ca2+ sensitivity in rabbit and human heart tissues. The aim of this study was to evaluate the effect of nebivolol in cardiac muscle strips of an established HCM Mybpc3 mouse model. Furthermore, we investigated actions of nebivolol and epigallocatechin-gallate, which has been shown to desensitize myofilaments for Ca2+ in mouse and human HCM models, in cardiac strips of HCM patients with a mutation in the most frequently mutated HCM gene MYBPC3. Methods and Results: Nebivolol effects were tested on contractile parameters and force-Ca2+ relationship of skinned ventricular muscle strips isolated from Mybpc3-targeted knock-in (KI), wild-type (WT) mice and cardiac strips of three HCM patients with MYBPC3 mutations. At baseline, KI strips showed no difference in maximal force development compared to WT mouse heart strips. Neither 1 nor 10 μM nebivolol had an effect on maximal force development in both genotypes. 10 μM nebivolol induced myofilament Ca2+ desensitization in WT strips and to a greater extent in KI strips. Neither 1 nor 10 μM nebivolol had an effect on Ca2+ sensitivity in cardiac muscle strips of three HCM patients with MYBPC3 mutations, whereas epigallocatechin-gallate induced a right shift in the force-Ca2+ curve. Conclusion: Nebivolol induced a myofilament Ca2+ desensitization in both WT and KI strips, which was more pronounced in KI muscle strips. In human cardiac muscle strips of three HCM patients nebivolol had no effect on myofilament Ca2+ sensitivity.
Related Concept Videos
Heart Failure Drugs: β-Blockers
Cardiomyopathy III: Hypertrophic Cardiomyopathy

